Skip to main content

Rush Biomarker Development Core

From biomarker discovery to analytically rigorous, clinically meaningful assays.

The Rush Biomarker Development Core is a translational research resource structured to convert biological discoveries into robust biomarker measurements and deployable research assays. The Core combines multi-plex immunoassay technology, custom assay development, quantitative proteomics, laboratory automation and expert scientific consultation to support projects from early discovery and feasibility studies through analytical validation and potential clinical research or industry partnerships.

Our model is intentionally collaborative. Rather than simply generating data, we work with investigators to define the biological question, select the most informative measurement strategy, optimize assay performance, address pre-analytical and matrix effects, establish quality-control criteria and interpret results in the context of the study objective.

A Translational Core Devised for Development

Many biomarker projects fail in the transition between discovery and practical measurement. The Rush Biomarker Development Core is designed to bridge that gap through the full translational continuum:

  1. Discovery and prioritization. Identify and prioritize candidate biomarkers using multi-plex protein profiling, proteomic discovery platforms, autoantibody approaches, and complementary molecular data.
  2. Assay design and development. Translate promising signals into fit-for-purpose assays using commercial reagents or custom antibody/antigen configurations, including multi-plex formats.
  3. Analytical characterization. Evaluate sensitivity, dynamic range, precision, reproducibility, recovery, dilutional linearity, matrix effects and other performance characteristics appropriate to the intended research use.
  4. Orthogonal validation. Confirm discovery findings using complementary quantitative technologies and independent assay formats.
  5. High-throughput clinical testing. Apply optimized workflows to low-volume, clinically annotated specimens using automated liquid handling and standardized quality-control procedures.
  6. Translational interpretation. Integrate biomarker data with clinical, pathological, and molecular information to support publications, grants, diagnostic-development programs, and future validation studies.

Why Work with the Biomarker Development Core?

  • Development expertise, not just fee-for-service testing. Projects can begin with a biological question rather than a pre-selected kit.
  • Multiplex capability with minimal specimen requirements. The Luminex xMAP/FLEXMAP 3D platform measures large analyte panels from low-microliter sample volumes.
  • Custom assay engineering. We develop and optimize assays for proteins, modified proteins, signaling targets, and antibody responses when commercial solutions are insufficient or unavailable.
  • Experience with clinical specimens. Protocols are designed around the realities of serum, plasma, cerebrospinal fluid, urine, saliva, dried blood spots, cell-culture media, and other complex biological matrices.
  • Orthogonal validation. The Core can help investigators confirm findings generated by discovery platforms such as mass spectrometry, Olink and other high-dimensional technologies.
  • Automation and scalability. Automated liquid-handling and plate-processing workflows improve throughput, reproducibility and consistency across large translational studies.
  • Scientific partnership. Core leadership provides extensive experience in translational oncology, diagnostic test development, proteomics, immunoassays, biobanking, and clinically annotated research cohorts.
  • Grant and industry readiness. Support is offered for study design, feasibility assessment, method development, budgets, grant applications, manuscripts and industry-sponsored research.
  • Investigator-level scientific collaboration. For projects in which biomarker development represents a significant scientific component, Core Director Jeffrey A. Borgia, PhD, is available to serve as a Co-Investigator and contribute to study design, biomarker strategy, assay development, validation, and translational planning.

Core Capabilities

Multi-plex Protein Biomarker Analysis
Quantitative and semi-quantitative measurement of cytokines, growth factors, soluble receptors, immune mediators, tumor-associated proteins and other analytes using bead-based multi-plex immunoassays. Projects range from focused panels to broad discovery-oriented profiling. 

Custom Immunoassay Development
Development and optimization of single- and multi-plex assays for targets not adequately addressed by off-the-shelf products. Applications can include native proteins, post-translationally modified proteins, phosphoproteins, glycoproteins, and other specialized targets. 

Autoantibody and Serologic Assay Development
Measurement of circulating antibody responses and development of customized serologic assays for translational research, including oncology, immune-response and infectious disease applications. 

Proteomic Discovery and Quantitative Validation
Support for protein biomarker discovery and orthogonal validation strategies, including integration with mass-spectrometry-based workflows and targeted quantitative follow-up. 

Biomarker Qualification and Analytical Validation
Fit-for-purpose characterization of assay performance, including reproducibility, precision, sensitivity, specificity, recovery, dilutional linearity, dynamic range and matrix-related effects. 

High-Throughput Specimen Processing
Automated workflows for plate-based specimen handling, dilution, reagent dispensing, washing and assay processing, enabling consistent handling of large clinical research cohorts. 

Data Analysis and Translational Interpretation
Assistance with assay normalization, quality-control review, curve fitting, exploratory statistical analysis and interpretation of biomarker patterns in relation to clinical or experimental endpoints. 

Study Design and Scientific Consultation
Early-stage consultation on experimental design, biospecimen selection, assay feasibility, sample-size considerations, technology choice, project workflow and future validation strategy.

Applications

The Core supports basic, translational, and clinical investigators across disease areas. Common applications include:

  • Early disease detection and screening biomarker development
  • Risk stratification and prognostic biomarker studies
  • Predictive and pharmacodynamic biomarker development
  • Treatment-response and resistance monitoring
  • Immune and inflammatory profiling
  • Autoantibody and serologic profiling
  • Companion and complementary diagnostic research
  • Validation of high-dimensional discovery data, including phosphoprotein analysis
  • Pilot studies supporting external grant applications
  • Industry-sponsored translational research and clinical-development programs

An Integrated Translational Environment

A unique strength of the Rush Biomarker Development Core is its integration within a broader translational research ecosystem. Core leadership also directs the Rush Cancer Center Biorepository, creating opportunities to align assay development with clinically annotated biospecimens, longitudinal patient data and complementary molecular profiling. This environment is especially valuable for studies that require iterative movement between discovery, validation, and clinically anchored interpretation.

The program has been used to support biomarker and diagnostic-development efforts spanning lung-cancer screening, indeterminate pulmonary nodules, early-stage recurrence risk, treatment response, immune profiling, cancer cachexia and other clinically important questions. Its broader research portfolio has included federally funded investigations and collaborations with diagnostic, biotechnology, and biopharmaceutical partners.

Technology and Instrumentation

Luminex FLEXMAP 3D / xMAP Technology
The principal multi-plex platform enables high-throughput measurement of large analyte panels while requiring small specimen volumes. The system supports commercial assays and custom-developed bead-based immunoassays.
Agilent Bravo Automated Liquid Handling
Programmable liquid handling maximizes reproducible, scalable plate-based workflows for specimen preparation, dilution, reagent dispensing and assay execution.
BioTek 405 TS Microplate Washer
Automated plate washing for 96- and 384-well formats standardizes immunoassay workflows and reduces operator-dependent variability.
Quantitative Proteomics Infrastructure
Available proteomic capabilities include Agilent liquid chromatography and triple-quadrupole mass spectrometry resources for targeted and quantitative protein-measurement applications.
Analysis Software
Dedicated immunoassay curve-fitting and statistical software, including Belysa and GraphPad Prism, substantiate assay analysis and quality control for project-specific computational reviews.

Scientific Collaboration and Project Development

Investigators are encouraged to involve the Core early. A brief consultation may identify opportunities to reduce specimen requirements, improve assay robustness, select better-performing reagents, avoid pre-analytical confounders and design a validation path that is appropriate for the intended biological or clinical question.

For competitive grant and contract applications, the Core can provide assistance with technical strategy, method development, feasibility assessment, cost estimates, and development plans. For ongoing projects, Core personnel may assist with methods, quality-control reporting, data interpretation, and manuscript preparation.

Leadership

Jeffrey A. Borgia, PhD — Director

Borgia is a translational cancer researcher and protein biochemist whose work focuses on the development of clinically relevant diagnostic and prognostic tests using proteomics, multi-plex immunoassays, molecular profiling and deeply annotated patient biospecimens. He directs both the Rush Biomarker Development Core and the Rush Cancer Center Biorepository and holds faculty appointments in Anatomy & Cell Biology and Pathology.

His research program has advanced biomarker concepts from discovery through assay development, analytical validation, clinical investigation, intellectual property, and commercialization. His portfolio includes more than 120 peer-reviewed publications, multiple issued and pending diagnostic patents, federally funded research, and extensive collaborations with biotechnology, diagnostic and biopharmaceutical partners.

David Gerard, MS — Core Supervisor

Gerard oversees day-to-day Core operations and project execution. He brings extensive experience in cell biology, biochemistry, laboratory management, assay troubleshooting and research workflow implementation, and serves as a primary operational contact for active and prospective projects.

Selected Examples of Translational Impact

The Core's value is best reflected by the types of problems it resolves - converting complex biological signals into reproducible measurements that can be tested in real clinical cohorts.

  • Development of blood-based biomarker strategies for lung cancer screening and malignancy-risk assessment of indeterminate pulmonary nodules.
  • Multiplexed serologic and autoantibody assays to investigate tumor-associated immune responses and treatment-related biology.
  • Custom immunobead approaches for longitudinal monitoring of antibody responses, including development of an in-house multi-plex SARS-CoV-2 serology assay.
  • Protein biomarker studies of cancer cachexia and systemic host-response pathways in patients with lung cancer.
  • Orthogonal validation and translation of high-dimensional discovery signals into practical quantitative assays for clinical research.

Selected Publications

The Biomarker Development Core is more than an analytical service. Its technologies and scientific expertise have contributed to peer-reviewed studies spanning biomarker discovery, assay development, and analytical validation through application in large clinical cohorts and multidisciplinary translational research. Selected examples include:

  • Auger C, et al. Analytical Validation of Dried Blood Spot Cards for Assessing COVID-19 Seropositivity. J Appl Lab Med. 2026;11(3):518-530. PMID: 41739739. 
  • Jackson L, et al. Exploratory Algorithms to Aid in Risk of Malignancy Prediction for Indeterminate Pulmonary Nodules. Cancers (Basel). 2025;17(7):1231. PMID: 40227817.
  • Shull T, et al. Elevated Neuroinflammation, Autoimmunity, and Altered IgG Glycosylation Profile in the Cerebral Spinal Fluid of Severe COVID-19 Patients. Brain Behav Immun. 2025;128:289-302. PMID: 40157461.
  • Aboushaala K, et al. Gut Microbiome Dysbiosis Is Associated with Lumbar Degenerative Spondylolisthesis in Symptomatic Patients. JOR Spine. 2024;7(4):e70005. PMID: 39398942.
  • Halloway S, et al. The MindMoves Trial: Cross-Sectional Analyses of Baseline Vascular Risk and Cognition in Older Women with Cardiovascular Disease. J Alzheimers Dis. 2024;100(4):1407-1416. PMID: 39031356.
  • Aboushaala K, et al. Discovery of Circulating Blood Biomarkers in Patients with and without Modic Changes of the Lumbar Spine: A Preliminary Analysis. Eur Spine J. 2024;33(4):1398-1406. PMID: 38451373.
  • Anderson KD, et al. Zucker Diabetic-Sprague Dawley Rats Have Impaired Peri-Implant Bone Formation, Matrix Composition, and Implant Fixation Strength. JBMR Plus. 2023;7(11):e10819. PMID: 38025036.
  • Auger C, et al. Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with “Actionable” Pulmonary Nodules. Cancers (Basel). 2023;15(8):2259. PMID: 37190187.
  • Ash MK, et al. Bulk IgG Glycosylation Predicts COVID-19 Severity and Vaccine Antibody Response. Cell Rep. 2022;41(11):111799. PMID: 36493786.
  • Jeanblanc N, et al. Development of Exploratory Algorithms to Aid in Risk of Malignancy Prediction of Indeterminate Pulmonary Nodules. Clin Chim Acta. 2022;535:197-202. PMID: 36087784.

Start a Project

Have a biomarker question but not yet an assay? Start with a conversation. The Core can help determine the most appropriate development path, from commercial multi-plex testing to a fully customized assay strategy.

For new projects, please provide a brief description of the biological question, specimen type, approximate number of samples, analytes or pathways of interest, anticipated timeline and funding source. Core staff will subsequently recommend an approach and provide a project-specific estimate.

Contact

Rush Biomarker Development Core
Jelke Building South, Suite 1401A
1750 W. Harrison St.
Chicago, IL 60612

Core Supervisor: David Gerard, MS (Primary Contact)
Email: david_gerard@rush.edu
Phone: (312) 942-3889

Core Manager: Kelly Cagin, PhD
Email: kelly_m_cagin@rush.edu

Core Director: Jeffrey A. Borgia, PhD
Email: jeffrey_a_borgia@rush.edu

Message us via Teams at: RES--Biomarker Development Core